COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #146 of 258
9/29 Late treatment study
Dabbous et al., Research Square, doi:10.21203/ (Preprint)
A Randomized Controlled Study Of Favipiravir Vs Hydroxychloroquine In COVID-19 Management: What Have We Learned So Far?
Source   PDF   Share   Tweet
Small RCT comparing HCQ and favipiravir, with 50 patients in each arm, finding that 55.1% of HCQ patients were PCR negative on day 7 compared to 48% for favipiravir, p = 0.7. There was no comparison with a control group.

Dabbous et al., 9/29/2020, preprint, 11 authors.
Details of all 258 studies    Meta analysis
Please send us corrections, updates, or comments.